Coherus BioSciences Management to Present at the 2018 Cantor Global Healthcare Conference in October

REDWOOD CITY, Calif., Sept. 17, 2018 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: CHRS), today announced that senior management will be presenting at the 2018 Cantor Global Healthcare Conference being held in New York on Tuesday, October 2, 2018 at 8:00 am ET.

The audio portion of the presentation will be available on the investors page of the Coherus BioSciences website at http://investors.coherus.com.

About Coherus BioSciences, Inc.
Coherus is a leading biosimilar company that develops and commercializes high-quality therapeutics for major regulated markets. Biosimilars are intended for use in place of existing, branded biologics to treat a range of chronic and often life-threatening diseases, with the potential to reduce costs and expand patient access. Composed of a team of proven industry veterans with world-class expertise in process science, analytical characterization, protein production, sales & marketing and clinical-regulatory development, Coherus is positioned as a leader in the global biosimilar marketplace. Coherus is advancing three late-stage clinical products towards commercialization, UDENYCA™ (pegfilgrastim-cbqv), CHS-1420 (adalimumab biosimilar) and CHS-0214 (etanercept biosimilar), as well as developing a robust pipeline of future products in ophthalmology (including CHS-3351, a ranibizumab biosimilar, and CHS-2020, an aflibercept biosimilar), as well as CHS-131, a small molecule for nonalcoholic steatohepatitis (NASH) and multiple sclerosis.  For additional information, please visit www.coherus.com.

CONTACT:
Jean-Frédéric Viret, Ph.D.
Chief Financial Officer
Coherus BioSciences, Inc.
jviret@coherus.com
+1 (650) 649-3546